0 results for 'Sanofi US Services Inc'
Lawsuit Linking Zantac to Cancer Diagnoses Survives Fight Over Jurisdiction
Waterbury Superior Court Judge W. Glen Pierson ruled that defendants, having registered to do business in Connecticut, consented to the jurisdiction of the state's courts.Hundreds of Plaintiffs Deploy Litigation Strategy in Zantac Suits
"Juries can be fickle, and if you have to try nine cases nine times, you may get nine different results," Peter Bowman, a personal injury lawyer for BBB Attorneys, said.Longtime Paris-Based McDermott Partner Joins Rimon in Texas
"Texas is the place to be," said Nicolas Lafont, the latest Rimon lateral hire to cite the firm's rate flexibility as a key reason for his move.Longtime France-Based McDermott Partner Joins Rimon in Texas
"Texas is the place to be," said Nicolas Lafont, the latest Rimon lateral hire to cite the firm's rate flexibility as a key reason for his move.View more book results for the query "Sanofi US Services Inc"
As Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify their class.Civil RICO Suit Accuses Big Pharma and Benefit Managers of Insulin Price-Fixing
"Rather than working to lower insulin and other Type 2 diabetes medication prices, major [pharmacy benefit managers] and manufacturers use their dominant market positions to drastically increase the price of these necessary, life-saving medications, generating billions of dollars in illicit profits," co-lead counsel for the plaintiff claimed in a joint statement.Boosted by Litigation, IP and Regulatory Work, Revenue Ticks Up at Wilson Sonsini
Demand varied across the firm's corporate practices, but some areas, such as environmental work, privacy and cybersecurity, were busy.Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Judge Rejects Class Action Claim Filed Against Novo Nordisk, Eli Lilly and Sanofi-Aventis
"Plaintiffs have not sufficiently shown they failed to receive the benefit of the bargain as they have not alleged that they had 'a reasonable belief about the product induced by a misrepresentation'—and in fact they have asserted the opposite, that their ascertainable loss theory is not based on misrepresentation—or that they were misled into buying insulin that was worth less than was promised," Judge Brian R. Martinotti said.Trending Stories
Why Are So Many Law Firms Suddenly Embracing Digital Transformation?
Brought to you by AllRize
Download Now
2025 State Legislative Sessions
Brought to you by LexisNexis®
Download Now
Retention & Online Reputation for Law Firms: 2025 Guide
Brought to you by Amazing Workplace, Inc.
Download Now
Europe's Escalating Regulatory Framework: Mapping Efforts to Mitigate Supply Chain Risks
Brought to you by LRN
Download Now